首站-论文投稿智能助手
典型文献
CAR T cells redirected against tumor-specific antigen glycoforms:can low-sugar antigens guarantee a sweet success?
文献摘要:
Immune-based therapies have experienced a pronounced breakthrough in the past decades as they acquired multiple US Food and Drug Administration(FDA)approvals for various indications.To date,six chimeric antigen receptor T cell(CAR-T)therapies have been permitted for the treatment of certain patients with relapsed/refractory hematologic malignancies.However,several clinical trials of solid tumor CAR-T therapies were prematurely terminated,or they reported life-threatening treatment-related damages to healthy tissues.The simultaneous expression of target antigens by healthy organs and tumor cells is partly responsible for such toxicities.Alongside targeting tumor-specific antigens,targeting the aberrantly glycosylated glycoforms of tumor-associated antigens can also minimize the off-tumor effects of CAR-T therapies.Tn,T,and sialyl-Tn antigens have been reported to be involved in tumor progression and metastasis,and their expression results from the dysregulation of a series of glycosyltransferases and the endoplasmic reticulum protein chaperone,Cosmc.Moreover,these glycoforms have been associated with various types of cancers,including prostate,breast,colon,gastric,and lung cancers.Here,we discuss how underglycosylated antigens emerge and then detail the latest advances in the development of CAR-T-based immunotherapies that target some of such antigens.
文献关键词:
作者姓名:
Pooria Safarzadeh Kozani;Pouya Safarzadeh Kozani;Fatemeh Rahbarizadeh
作者机构:
Department of Medical Biotechnology,Faculty of Medical Sciences,Tarbiat Modares University,Tehran,P.O.Box 14115/111,Iran;Department of Medical Biotechnology,Faculty of Paramedicine,Guilan University of Medical Sciences,Rasht,P.O.Box 44771/66595,Iran;Research and Development Center of Biotechnology,Tarbiat Modares University,Tehran,P.O.Box 14115/111,Iran
文献出处:
引用格式:
[1]Pooria Safarzadeh Kozani;Pouya Safarzadeh Kozani;Fatemeh Rahbarizadeh-.CAR T cells redirected against tumor-specific antigen glycoforms:can low-sugar antigens guarantee a sweet success?)[J].医学前沿,2022(03):322-338
A类:
glycoforms,Alongside,sialyl,Cosmc,underglycosylated
B类:
CAR,cells,redirected,against,tumor,specific,low,sugar,antigens,guarantee,sweet,success,Immune,have,experienced,pronounced,breakthrough,past,decades,they,acquired,multiple,US,Food,Drug,Administration,FDA,approvals,various,indications,To,date,six,chimeric,receptor,been,permitted,treatment,certain,patients,relapsed,refractory,hematologic,malignancies,However,several,clinical,trials,solid,were,prematurely,terminated,reported,life,threatening,related,damages,healthy,tissues,simultaneous,expression,by,organs,partly,responsible,such,toxicities,targeting,aberrantly,associated,also,minimize,off,effects,Tn,involved,progression,metastasis,their,results,from,dysregulation,series,glycosyltransferases,endoplasmic,reticulum,protein,chaperone,Moreover,these,types,cancers,including,prostate,breast,colon,gastric,lung,Here,discuss,how,emerge,then,detail,latest,advances,development,immunotherapies,that,some
AB值:
0.596422
相似文献
TMEM106A transcriptionally regulated by promoter methylation is involved in invasion and metastasis of hepatocellular carcinoma
Shiming Shi;Biao Wang;Jinglei Wan;Lina Song;Guiqi Zhu;Junxian Du;Luxi Ye;Qianqian Zhao;Jialiang Cai;Qing Chen;Kun Xiao;Jian He;Lei Yu;Zhi Dai-Liver Cancer Institute,Zhongshan Hospital,Fudan University&State Key Laboratory of Genetic Engineering,Fudan University,Shanghai 200032,China;Department of Radiation Oncology,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Department of Pediatric Surgery,the First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510080,China;Department of General Surgery,Zhongshan Hospital(South),Fudan University,Shanghai Public Health Clinical Center,Fudan University,Shanghai 200083,China;Department of Gastrointestinal Surgery,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China;Department of Liver Surgery and Transplantation,Liver Cancer Institute,Zhongshan Hospital,Fudan University,Shanghai 200032,China
Pharmacodynamic,pharmacokinetic,and phase 1a study of bisthianostat,a novel histone deacetylase inhibitor,for the treatment of relapsed or refractory multiple myeloma
Yu-bo Zhou;Yang-ming Zhang;Hong-hui Huang;Li-jing Shen;Xiao-feng Han;Xiao-bei Hu;Song-da Yu;An-hui Gao;Li Sheng;Ming-bo Su;Xiao-li Wei;Yue Zhang;Yi-fan Zhang;Zhi-wei Gao;Xiao-yan Chen;Fa-jun Nan;Jia Li;Jian Hou-National Center for New Drug Screening,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Yantai Key Laboratory of Nanomedicine&Advanced Preparations,Yantai Institute of Materia Medica,Yantai 264000,China;Department of Hematology,Renji Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200127,China;Shanghai Center for Drug Metabolism and Pharmacokinetics Research,Shanghai 201203,China
Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment
Da-cai Xu;Li Yang;Pei-quan Zhang;Ding Yan;Qian Xue;Qing-tian Huang;Xiao-fen Li;Ya-li Hao;Dao-lin Tang;Q.Ping Dou;Xin Chen;Jin-bao Liu-Affliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;The Department of Physiology,School of Basic Medical Sciences,Guizhou Medical University,Guiyang 550003,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。